NCT07216781 Safety and Efficacy of Injectable Klotho Plasmid Gene Therapy in Humans
| NCT ID | NCT07216781 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Minicircle |
| Condition | Healthy Adults |
| Study Type | INTERVENTIONAL |
| Enrollment | 24 participants |
| Start Date | 2025-10-06 |
| Primary Completion | 2026-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 24 participants in total. It began in 2025-10-06 with a primary completion date of 2026-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to investigate the safety and efficacy of a gene therapy for Klotho, delivered via a nonviral plasmid in healthy adult volunteers. Additionally, this study seeks to understand the cognitive and health benefits of the Klotho gene therapy.
Eligibility Criteria
Inclusion Criteria: * Participant is open to morphological change * If female, participant agrees to maintain contraception * If female, participant agrees to take a pregnancy test * If female, participant agrees to a pregnancy waiver Exclusion Criteria: * Women of childbearing potential who are unwilling or unable to use effective contraception for the duration of the study * History of cancer diagnosis * Preexisting medical issues that may be exacerbated by the treatment * Has received any gene therapy within the past 12 months * Unwilling or unable to provide written informed consent
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07216781 clinical trial?
This trial is open to participants of all sexes, aged 23 Years or older, up to 90 Years, studying Healthy Adults. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07216781 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07216781 currently recruiting?
Yes, NCT07216781 is actively recruiting participants. Contact the research team at mac@minicircle.io for enrollment information.
Where is the NCT07216781 trial being conducted?
This trial is being conducted at Austin, United States, Roatán, Honduras.
Who is sponsoring the NCT07216781 clinical trial?
NCT07216781 is sponsored by Minicircle. The trial plans to enroll 24 participants.